These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation. Brizendine KD; Richter SS; Cober ED; van Duin D Antimicrob Agents Chemother; 2015 Jan; 59(1):553-7. PubMed ID: 25385105 [TBL] [Abstract][Full Text] [Related]
4. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Nguyen M; Eschenauer GA; Bryan M; O'Neil K; Furuya EY; Della-Latta P; Kubin CJ Diagn Microbiol Infect Dis; 2010 Jun; 67(2):180-4. PubMed ID: 20356699 [TBL] [Abstract][Full Text] [Related]
5. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy. Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374 [TBL] [Abstract][Full Text] [Related]
6. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. van Duin D; Cober E; Richter SS; Perez F; Kalayjian RC; Salata RA; Evans S; Fowler VG; Kaye KS; Bonomo RA J Antimicrob Chemother; 2015 Apr; 70(4):1203-11. PubMed ID: 25492391 [TBL] [Abstract][Full Text] [Related]
7. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections. Ny P; Nieberg P; Wong-Beringer A Am J Infect Control; 2015 Oct; 43(10):1076-80. PubMed ID: 26190386 [TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Carbapenem-resistant Wang Z; Qin RR; Huang L; Sun LY Chin Med J (Engl); 2018 Jan; 131(1):56-62. PubMed ID: 29271381 [TBL] [Abstract][Full Text] [Related]
9. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Giamarellou H; Galani L; Baziaka F; Karaiskos I Antimicrob Agents Chemother; 2013 May; 57(5):2388-90. PubMed ID: 23439635 [TBL] [Abstract][Full Text] [Related]
12. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086 [TBL] [Abstract][Full Text] [Related]
13. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Ceccarelli G; Falcone M; Giordano A; Mezzatesta ML; Caio C; Stefani S; Venditti M Antimicrob Agents Chemother; 2013 Jun; 57(6):2900-1. PubMed ID: 23571536 [No Abstract] [Full Text] [Related]
14. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M; Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283 [TBL] [Abstract][Full Text] [Related]
15. Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae. Wu D; Cai J; Liu J South Med J; 2011 Feb; 104(2):106-10. PubMed ID: 21258230 [TBL] [Abstract][Full Text] [Related]
16. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. Oliva A; D'Abramo A; D'Agostino C; Iannetta M; Mascellino MT; Gallinelli C; Mastroianni CM; Vullo V J Antimicrob Chemother; 2014 Jun; 69(6):1718-20. PubMed ID: 24521856 [No Abstract] [Full Text] [Related]
17. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Viale P; Giannella M; Lewis R; Trecarichi EM; Petrosillo N; Tumbarello M Expert Rev Anti Infect Ther; 2013 Oct; 11(10):1053-63. PubMed ID: 24073806 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India. Kaur A; Gandra S; Gupta P; Mehta Y; Laxminarayan R; Sengupta S Am J Infect Control; 2017 Nov; 45(11):1289-1291. PubMed ID: 28807425 [TBL] [Abstract][Full Text] [Related]
20. A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study). Mustafa M; Chan WM; Lee C; Harijanto E; Loo CM; Van Kinh N; Anh ND; Garcia J Int J Antimicrob Agents; 2014 Apr; 43(4):353-60. PubMed ID: 24636429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]